Metabolomics for Bioactivity Assessment of Natural Products

Nancy Dewi Yuliana\textsuperscript{1,2}, Alfi Khatib\textsuperscript{2,3}, Young Hae Choi\textsuperscript{1}, Robert Verpoorte\textsuperscript{1}

\textsuperscript{1}Div. Pharmacognosy, Section Metabolomics, Institute of Biology, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
\textsuperscript{2}Dept. Food Science and Technology, Bogor Agricultural University, IPB Dramaga Campus, Bogor, Indonesia
\textsuperscript{3}Center of Excellence for Food Safety Research, Faculty of Food Science and Technology, University Putra Malaysia, 43400 Serdang, Selangor Darul Ehsan, Malaysia.

Abstract

Natural products (NP) have historically been a rich source of lead molecules in drug discovery based on their capability to create unique and diverse chemical structures. However, it is true that the vast number of metabolites typically present in natural products and their huge dynamic range results in the loss of many possibly bioactive natural compounds, becoming an inextricable obstacle for drug development. Recently, new strategies which favor a holistic approach as opposed to the traditional reductionist methods previously used have been introduced with the purpose of overcoming the bottlenecks in natural product research. This approach is based on the application of new technologies, including metabolomics, for example. Metabolomics allows a systematic study of a complex mixture such as phytochemical preparation, which can be linked to observations obtained through biological testing systems without the need of isolating active principles. This may put drug discovery from natural products back in the limelight again. In this review paper, the description of some examples of successful metabolomics applications in several important fields related to drug discovery from natural sources aims at raising the potential of metabolomics in reducing the gap between natural products and modern drug discovery demand.

Key words: natural products, drug discovery, bioactivity, metabolomics

Chapter 4

**Introduction**

In recent years the development of novel drugs has become increasingly difficult, expensive and time consuming. It is estimated that more than 800 million USD and an average of 14.2 years are needed for a novel drug application (NDA) approval. Both factors are rapidly increasing with time while the output of newly launched drugs has dropped (332, 333). The introduction of high throughput screening (HTS), a process which allows the testing of a large number of samples on certain molecular targets, was expected to shorten the discovery route. To fully use its high potential, HTS requires a large number of compounds to screen, in the order of thousands of samples per day (334). In order to meet this demand, high throughput synthesis and combinatorial chemistry were developed. Concomitantly, further development in the field of structural biology and genomics, e.g. cloning and expression technology resulting in the production of various purified human receptors and enzymes which could be studied at a molecular level, produced a sharp increase in the number of possible molecular targets, demanding more drug-based libraries of a wide chemical diversity to screen (335). The combination of these new strategies seemed very powerful and the delivery of a large number of novel leads was expected (336). However, these expectations were shown to be greatly overrated as the number of new active compounds that made it to the market in the past two decades reached its lowest level ever in 2002 with an insignificant improvement in 2003 (1, 336, 337). Sorafenib, a multikinase inhibitor indicated for advanced renal cancer, is the single synthetic drug derived from combinatorial chemistry approved by Food and Drug Administration for clinical use (1). The fact, this increased HTS screening capacity and number of novel molecular targets has failed to produce an increase of new lead compounds poses the question on whether this is due to limitations in the innovative aspects of the discovery process itself, e.g. generation of compounds limited chemical diversity, or because of the potential of natural products (NP) has been de-emphasized in the past few years (332).

The possibility of combining NP extract libraries with HTS also seems interesting, though not always an easy task. Several reasons for the incompatibility of NP and HTS have been described (332, 336). The complexity of NP extract which is a complex mixture of mostly uncharacterized compounds which may mask the bioactivity
of target compounds or cause false positive results is the most common hurdle. The large dynamic range (e.g. the difference in the levels of major compounds as compared to that of minor compounds, differences in polarity, in boiling or evaporating points, etc) which may affect compounds solubility makes the integration of NP and HTS more complicated. The differences between areas where plants are grown, the methods of production and processing of plants are also important since these might affect the chemical profile of the NP (338, 339). The intellectual property issue in natural product outsourcing is another problem. Thus, the drug discovery process using plant sources was almost abandoned (333, 340). Companies such as Glaxo Wellcome, Smith Kline & French, and Pfizer, gradually eliminated their NP screening programmes while others such as Merck and Novartis continued their exploration but focussed on microbial sources (336).

The failure to increase the number of new drugs delivered to the market has placed the drugs discovery programs of pharmaceutical companies under scrutiny. Looking back to the past two decades, of the 877 novel medicines developed between 1981 and 2002, 6% were NP, 27% were NP derivatives and 16% were synthetic products developed on the basis of a NP model (337), indicating that NP is still an important source of novel leads for therapeutical drugs. This situation has led to a renewed interest in NP in the drug discovery programs. Therefore, it is a challenging task to make NP available for the drug discovery arena.

Most NP drug discovery work follows ‘the silver bullet’ approach as is usual in present Western medicine, in which the search is focused on single compounds with a particular biological activity (single target-single compound paradigm) tested at molecular level (e.g. receptor binding inhibition or enzyme screening) (341). This approach which has been responsible for the successful delivery of many potent drugs in the past, such as the statins to lower cholesterol level and huperzine A for Alzheimer’s disease (342), is not actually the best approach for NP studies since the presence of synergism and pro-drugs in an extract can be misleading (341). It is also one of the reasons for the long time line and high costs which the pharmaceutical companies have to deal with when working with NP. Shifting the silver bullet paradigm to a more holistic approach, which is actually the philosophy of some traditional medicine such as Traditional Chinese Medicine (TCM) and Ayurveda, is now evolving into a new trend.
In a holistic approach, a whole herbal preparation, which consists of numerous multi components, is viewed as one active entity with effects on multiple targets in living organisms. For such an approach, the response of the whole system needs to be observed with all possible tools such as clinical trials or experimental animal models, where both classic physiological observations (e.g. blood pressure, analgesic activity, sedative) and modern molecular observation (gene expression, proteome, metabolome) can be used to obtain better insight into different changes in organism. This is known as a systems biology approach.

Among these ‘omics’ methods, metabolomics, a relatively new member, is thought to be the most informative as regards understanding systems biology since it reflects the genotype. Therefore it is a valuable tool to use in the provision of the information required in this new approach which is particularly interesting for the study of medicinal plants. It thus offers new opportunities for NP in the drug discovery arena.

This review will discuss the chemical diversity of compounds present in NP as compared to synthetic compounds, the obstacles which might limit NP integration with the new emerging drug discovery technologies, the shift in tendency from a reductionist to a holistic approach in NP research and how metabolomics can help to narrow the gap between NP and the demand of modern drug discovery, and helping to turn NP and medicinal plants into a unique drug source.

1. Natural products as a drug source; their advantages and limitations

Factors which distinguish NP from synthetic chemicals include their incomparable molecular diversity and biological functionality. Starting with only a few building blocks of NP provided by the biosynthetic pathways, the action of various “decorating” enzymes provide a large diversity of end products with different functionalities. Compared to products resulting from combinatorial chemistry libraries which usually lack chirality and structure rigidity, two important requirements for pharmaceutical drug-like properties, NP have privileged structures which are able to interact with proteins and other biological targets for specific purposes.

To address the question of how the unique structural properties of NP are able to complement the chemical space of synthetic compounds, the comparison of the major structural differences between combinatorial compounds, drugs, and NP molecules has
been made. It is obvious that current commercial drugs and NP share more similarities in several topological pharmacophore patterns. The important differences between NP and synthetic compounds include the number of chiral centers, the prevalence of aromatic rings, the presence of complex ring systems, and the degree of the saturation of the molecule as well as the number and ratios of different heteroatoms (348). Natural products have a higher number of chiral centers, a higher number of oxygen atoms instead of nitrogen, sulfur and halogen containing groups present than in synthetic compounds. Natural products have a lower ratio of aromatic ring atoms to total heavy atoms, and a higher number of solvated hydrogen bond donors and acceptor functional groups. These characteristics are favorable attributes for a drug candidate profile (1, 337, 348, 349). With these unique properties, in general, NP actually has more drug-like properties than synthetic compounds (348, 350).

However, a NP-based drug discovery project also poses some challenges, mostly connected with their presence within a complex matrix with all kind of active compounds (335, 336, 340, 347, 350-352):
- The first challenge is dereplication which is the rapid identification of known and unknown compounds from partially purified mixtures. In a number of test systems, common plant products which have been found to be active e.g. unsaturated fatty acids on adenosine and GABA receptors or tannins on enzymes based bioassays, have to be identified at the very beginning of the study of an active extract.
- Interaction between metabolites present in extracts. Extracts consist of mixtures of many compounds requiring an elaborate purification to isolate new pure compounds. Another problem of complex extracts is the presence of antagonism or synergisms which might occur between components in a mixture, posing a major intellectual challenge which can be painstakingly time consuming.
- Structure determination by spectroscopic methods.
- Large scale production of the active component is sometimes an obstacle as the identified NP lead might be a minor compound of the extract, or the supply of the material for extraction might be limited.
- Sourcing of authenticated plants, a very important issue for quality control. For example, some plants have congeners substitutes which have an active principal content which may be different to the original one.
Last but not least, biodiversity and intellectual property issues can be another complicating factor related to this context.

2. Previous efforts to increase the number of compounds for drug candidates

Because of the demand to speed up the drug discovery timeline and to reduce costs, the in-vitro screening system has become the preferred method. The use of animal tests or isolated organs was abandoned for more specific testing targets at a molecular level (reductionist mode) (353). Following this trend, there are two crucial prerequisites to start the drug discovery process: a large high quality library of candidates to be screened, and a reliable and sensitive assay to screen the activity. Combinatorial chemistry was developed to address the first need (354). Based on the total chemical space, this technology is theoretically able to provide $10^{30} - 10^{100}$ compounds (355, 356).

The second need was met by high throughput screening (HTS) as the response to the availability of hundreds to thousands of compounds resulting from combinatorial chemistry. High throughput screening is a fast and cost-effective technology designed to select drug candidates (357, 358). It is defined as an automatic approach in drug discovery which is characterized by miniaturization to allow the use of minute quantities of samples and reagent. Continuous innovations keep taking place to maximize the quantity of screened compounds and to minimize the cost. The miniaturization of screening assay aimed at increasing HTS capacity is achieved by increasing the screening plate density and minimizing screening volume (359). The system which enables the screening of 120,000 -240,000 compounds per day has been created by the use of high density 1,536 wells plates. Higher capacity plates of 3,456 wells are also available but used rarely due to the limitation determined by the low liquid volume delivery (360-362). Compounds found to be active in HTS are called “hits”, but the distance from a hit to a lead is very large. This requires more extensive screening for other activities, including toxicological evaluations. In this process similar compounds will be produced to optimize the activity profile.

However, compounds obtained from the screening are not always (physico) chemically and pharmacologically suitable for further development as a lead. While the in-vitro profile is maybe very promising, ADMET (absorption, distribution, metabolism, elimination, toxicity) properties are often poor (358). In most cases the
compound will require modifications to become a lead and drug candidate. Thus, the crucial bottleneck of lead development is not only hit identification, but the potential of the candidate to become a new drug (358).

Therefore it is necessary not to focus only on quantity but also consider quality of both library and assays. One suggestion made on this matter, was to introduce simple ADMET parameters at the early stage of screening and the more sophisticated ones at a later stage (188). The appropriate application of virtual screening as a complement to a screening campaign to enrich the hit rate and reduce the number of false positive has been suggested as well (358, 361-363). Most virtual screening is guided by the structure of the target protein and 3-dimensional descriptors of small molecular structures that fit into the protein active site. Further approaches such as the identification of active compounds by clustering and partitioning techniques, compound filtering to eliminate undesired compounds (e.g. toxicant and groups with poor aqueous solubility and passive absorption) can also be applied (362). Understanding the mechanism of action of a biological target is another approach. Several techniques have been reported, such as immobilization and stabilization of the target protein upon its ligand binding, as well as the use of nuclear magnetic resonance (NMR) spectroscopy coupled to other analytical methods to learn about the drug-protein interaction (363). For the targets without sufficient bio-structural information, such as in the area of G-protein coupled receptors (GPCRs), a ligand motif-based library design approach can be applied (358).

The aforementioned efforts, however, did not successfully fulfill the high expectation of increasing productivity. The tremendous amount of money spent was not counterbalanced with the number of new approved drugs (361). However, all these methods will result in all companies having the same basic information on targets and probably ending up with the same compound, reducing the chance for real innovation with this approach will be limited. This has encouraged reconsidering NP as a drug source.

3. Efforts to combine natural products with new technologies

Many studies reported possible approaches which could potentially help to overcome the above mentioned problems in the NP drug discovery process. Solutions to address the incompatibility of NP extracts with HTS technology were proposed,
including the generation of a high quality NP compound library, the improvement of fractionation methods, and of dereplication and identification steps.

3.1. Constructing a high quality natural product library

Several strategies to construct better NP libraries and to improve methods to screen these libraries have been reviewed. The advantages and limitations of a crude extract library, pre-fractionated library, or pure compound library have been described (350). Crude extract libraries are simple to make, the obstacles appearing in the identification and dereplication steps. A pre-fractionated library can be effective to overcome these hurdles since the less complex fractions require fewer purification steps and the interference of unwanted compounds is reduced, while more investment is required both for fraction preparation and for the HTS assay since several samples are obtained from a single extract. The pure compound library is preferred since it is able to move forward directly after finding a hit.

The strategy employed to build a fraction library as a compound source for HTS from Chinese herbal formulations reported to treat atherosclerosis has been described. Medium pressure liquid chromatography with a gradient solvent system followed by reverse phase semi-preparative HPLC was used as a filtering method to remove unfavorable compounds lacking desirable ADME properties and to prepare semi-crude extracts with different polarity. The fractions were characterized and identified by LC-DAD-ESI-MS. A component detection algorithm (CODA) was used to reduce noise and background of the chromatograms which then were presented as a histogram describing compound molecular distribution. Small molecules (less than 500 Da) were characterized by retention time, molecular weight, UV absorbance, and crude drug origin. In this way, 36 major compounds of each fraction were identified and after cell based multiples bioassay screening, validation and dereplication steps, 7 hits were found (364).

3.2. Improving fractionation methods

Another study focused on sample fractionation using an automatic multiple solid phase extraction (SPE) method (351). Several different solid phases were used
thus reducing the complexity of an extract from a microbial fermentation broth, leading to a more reliable and reproducible screening result.

3.3. Improving dereplication and identification steps

A fast dereplication and identification of novel active compounds can be achieved by direct coupling of the bioassay to liquid chromatography (362, 365). An example is the post-column acetylcholine esterase (AChE) inhibitor assay. After centrifugal partition chromatography (CPC) pre-fractionation and bioactivity testing, the most active *Narcissus* ‘Sir Winston Churchill’ fraction was injected into an online biochemical detection system coupling HPLC-UV-MS for AChE inhibitor activity. This system enabled a fast dereplication, allowing the identification of known compounds. It proved very useful for the detection of novel active compounds in the presence of known active compounds. For example, beside the well known galantamine, another active compound, ungiminorine, was identified (366). A similar technique was applied to screen for natural phosphodiesterase and estrogen receptor ligands (367, 368).

Sometimes, the information of molecular weight and UV spectra provided by combination of LC-DAD-MS is not sufficient for the identification of active compounds. The use of electrospray ionization Fourier Transform Ion Cyclotron Resonance MS (ESI-FTICR-MS) as a rapid and informative approach for direct affinity screening of bovine carbonic anhydrase II (bCAII) ligands from extracts was reported (369). The bCAII-ligand affinity is based on the non-covalent binding between the enzyme and the ligand. The electrospray ionization technique is known as a gentle ionization process that can transfer intact non-covalent complexes from the solution phase into the gas phase while the high resolution of the FTICR-MS allows the very accurate deduction of mass-to-charge ratio (m/z) of the protein-ligand complex from which even the molecular weight of this ligand can be calculated. This method was applied by separating small molecules from macromolecules by size exclusion chromatography (370), after the protein was added to the extract. This protein-ligand complex was then subjected to online SEC-ESI-FTICR-MS or directly infused into ESI-FTICR-MS, allowing the rapid determination of molecular weight of the active compound with an error below 0.08 Da. Bioactive compounds which were present in the mixture could be detected down to the level of 0.02% dry weight. HPLC coupled to
an on-line postcolumn antioxidant detection system in combination with absorbance spectrometry and quadrupole time-of-flight high-resolution MS (QTOF-MS) allowed the identification of compounds responsible for the antioxidant capacity of raspberry (*Rubus idaeus*) and their level during raspberry ripening stages and in different cultivars and different genetic background (371).

In a recent report, NMR based screening of bioactive NP and structure elucidation of the active compound in a single step was described (372). This study aimed at detecting ligands from plants that bind to a specific target protein, lectin. The interaction between a ligand present in the plant extract was detected by comparing the saturation transfer difference (STD) and NOESY spectra of target protein with and without extract. The most important structural information was provided by two dimensional NMR data such as TOCSY, HSQC, HMBC and selective 1D-COSY. Several LC-NMR hyphenation techniques and their application to advance plant extract profiling have been described (373). The advantage and limitation of continuous flow LC-NMR, stop flow LC-NMR, LC-NMR/MS, LC-SPE-NMR, and application of cryogenic and microflow technology have also been reviewed. The performance of these LC-NMR coupling technologies depends on many factors such as the physical connection of LC-NMR, flow-through probe design, and factors affecting NMR sensitivity (solvent compatibility, solvent suppression, the adequate sample volume). Practical examples of the application of various hyphenated LC-NMR techniques for rapid screening, dereplication, and structure determination of active compounds from natural extract has been published (374).

### 3.4. Virtual screening

The application of virtual screening of known NP has been proposed (375). NP are still an incredible rich source of new drugs and because of the better understanding of protein-ligand interaction properties, NP virtual screening can constitute an alternative way to accelerate the drug discovery process. Many advantages have been described including higher capacity, reduction in the number of experiments for testing and isolating compounds, the ability to calculate the possible interaction of compounds and targets, and the possibility of applying additional filters such as ADME and drug-like properties to improve the hit quality. Strategies to combine virtual screening and
classical methods in NP exploration were proposed; (1) Direct screening of a 3D database of NP using available target information and pharmacophore model of specific activity, followed by the isolation of hits once the results are confirmed by experimental data. (2) Extracts were roughly screened experimentally to select the active ones, or the specific activity was explored through an ethnopharmacological approach, the result of which was then virtually screened using a pharmacophore model of the target, followed by isolation.

4. Metabolomics

Metabolomics is one of the new ‘omics’ fields, joining genomics, transcriptomics, and proteomics (376). The general aim of metabolomics is the qualitative and quantitative analysis of all metabolites (the metabolome), present in an organism, at a specific time and under specific influence (12, 13, 343, 377, 378). A metabolome is the entire set of small molecules present in a cell, tissue, or organism under certain conditions and at certain point in time (343).

Metabolome components can be viewed as gene expression end products, thus its quantitative and qualitative measurement may provide a broad insight of the biochemical status of an organism and can be used to monitor gene function (344). The use of transcriptomics and proteomics profiles to predict gene function has been criticized because of limitations such as the fact that the changes in the transcriptome or proteome do not always correlate to biochemical phenotypes or that the translated protein may or may not be enzymatically active (344, 376, 379). The lack of a data base source may result in limited information since the identification of mRNA and proteins is based on sequence similarity or database matching. Therefore, among the ‘omics’ technologies, metabolomics can be viewed as the most functional approach (344). The combined information obtained from genomics, proteomics and metabolomics should be able to provide an integrated understanding of a cell or organism (343, 344).

4.1. Detection method

Compared to proteins and RNA, secondary metabolites have a much more diverse atomic arrangement which results in broad variations in chemical and physical properties, such as molecular weight, polarity, solubility, and volatility (380), and can
be present in a large range of concentrations (381). This generates technological
difficulties in the simultaneous profiling of all metabolites (344). There are thus
considerable challenges in metabolomics experiments such as sampling, sample
preparation, instrumental analysis, and then in the interpretation of the tremendous
amount and diversity of data arising from the metabolomics analysis (376, 382), the
construction of consolidated metabolite libraries and the development of metabolite-
specific data management systems (381). Therefore, metabolomics based work still
depends on further improvement of sampling, analyzing and computational technologies
(376, 382).

The identification and quantification techniques applied to metabolomic based
work have been comprehensively reviewed (344, 382-386). Many analytical methods
with better reliability, robustness, selectivity, and resolution, have been developed in
which instead of targeting on a few specific compounds, the aim is to identify and
quantitate multiple targets in order to obtain an overview of compounds classes (384).

The progressive development of ionization and mass detection methods, and
the ability to detect a wide range of molecular weight and polarities have become a
strong point for the use of MS and tandem MS techniques in metabolomics (386). Gas
chromatography coupled to MS (GC-MS) has been used to identify and elucidate the
structures of 326 different compounds from Arabidopsis thaliana leaf (387) and to
identify and classify 322 tomato volatiles from 94 genotypes according to their
biochemical precursor similarity (388).

Liquid chromatography (LC) is an alternative tool particularly for non-volatile
plant metabolites though it requires more technical support than GC (379, 380). An
open access database dedicated to LC-MS based metabolomics of tomato fruit (Solanum
lycopersicum) has been presented. A C18 base RP LC-photodiode array detection
(PDA)-electrospray ionization (6)-quadrupole time-of-flight (QTOF)-MS method was
developed for the detection and putative identification of predominantly semipolar
secondary metabolites. Some previously unreported novel compounds from tomato fruit
were identified by this means (381).

The use of laser desorption/ionization mass spectrometry on porous silica
(DIOS) and cluster analysis to discriminate the metabolic footprints of mutant yeast and
wild type yeast has been reported (389). Compared to matrix- assisted laser
desorption/ionization (390) mass spectrometry, DIOS-MS is much simpler, allowing the analysis of small molecules in absence of matrix ions with little or no fragmentation and better tolerability to moderate amounts of contaminants in the biological sample. Both methods are also especially effective for analysis of proteins and their derivatives (391).

Although MS sensitivity is probably the best among analytical methods, there are some limitations for its application in metabolomics. For example, the different sensitivity of the detection of molecules and its reproducibility are important issues. Because of different detector response, calibration curves are needed for each individual compound for absolute quantification, this being totally unrealistic considering the hundreds of signals that appear in a metabolomic profile. In this case, NMR spectrometry is the method of choice, in absence of which only a relative quantification of the individual compounds in different experiments can be made (386).

The application of NMR for metabolic profiling of plant tissue extracts has been reviewed by several authors (12, 13, 392). Reproducibility is the most important criteria for developing a metabolomics technology platform, and NMR is the most suited choice even though its sensitivity is not as high as MS (1 μM – 1 mM in NMR tube) (12, 13). The simple and fast sample preparation, short measurement time, the availability of less automatization and advanced data analysis methods, plus the possibility to elucidate structures of known or unknown compounds in a complex mixture using advanced two-dimensional (2D) NMR methods, are further advantages (12, 13).

4.2. Data processing

Data resulting from metabolomics based work are typically high dimensional data which require multivariate data analysis (MVDA) methods for interpretation. Most metabolomics data analysis methods are based on the classification of samples into different groups (e.g. treatment, genotype), both by supervised (e.g. discriminant function analysis, artificial neural networks) or unsupervised type data analysis method e.g. principal component analysis (PCA), hierarchical cluster analysis (HCA) (379). It is also possible to use MVDA to make a regression modeling between two blocks of data, usually denoted as X and Y. In metabolomics based NP studies, X may represent signals from different metabolites present in plant extracts which are sampled at regular time
Chapter 4

intervals, and Y the responses (e.g. quality of product, bioactivity, yield). The model
then can be used to predict Y from X which is obtained from new observations. The
most common MVDA method for this modeling is partial least square (PLS) method
(14). Some extended versions of PLS to improve the predictability power were
developed recently, such as orthogonal signal correction (OSC), orthogonal-PLS
(OPLS), and orthogonal-orthogonal-PLS (O2PLS) (393, 394)

5. Various applications of metabolomics in bioactivity screening of natural product

5.1. Metabolomics to improve identification and dereplication steps

The reductionist approach as described above is still widely applied in many
NP drug discovery projects, i.e. in bioassay guided isolation work. In this approach, the
rapid dereplication of known actives and identification of novel actives is essential.
Addressing this issue, some papers have described the way in which a metabolomics
approach consisting in the use of various analytical methods followed by appropriate
MVDA can be used to shorten the reductionist bioassay driven isolation route,
especially in the identification and dereplication step.

In one study, the hierarchical cluster (HCA) analysis of the chromatographic
profiles of 500 lipidic extracts of bacteria, resulted in the identification of 2 new
oligoprenylsesquiterpenes and 2 new N-(2-arylethyl) amides, though the bioactivity
profile was not reported here. The HCA was chosen instead of PCA since the number
of principal components representing more than 50% of the variance was much too high
for PCA. Principal component analysis is more suitable for a large data set of similar
compounds, which was not the case in this project. The use of this clustering method
was able to advance the dereplication step and to avoid redundant analyses for selection
of strains containing new NP (395).

The most time consuming step in metabolomics based work is the
identification of metabolites in a prefractionated mixture. The availability of a
compound spectral library is crucial for rapid identification. A free web-based tool
containing data related to primary and secondary metabolites from various species
based on NMR or MS data, the Madison Metabolomics Consortium Database (MMCD)
was developed (396). The sensitivity of MS and the feasibility of NMR spectroscopy,
including the application of two dimensional (2D) NMR followed by MVDA application, make these techniques particularly well suited for the characterization of crude unfractonated NP. The analysis based on double quantum filtered correlation spectroscopy (DQF-COSY) was introduced to simplify the analysis of 2D NMR spectra and has demonstrated its utility to detect previously unreported terpenoid indole alkaloids from *Tolypocladium cylindrosporum* grown in different media. Graphical analysis of the obtained spectra through multiplicative stacking and graphical manipulation of the bitmap spectra allowed signals only present in a specific media to be distinguished. Further structure elucidation was then performed by heteronuclear single quantum correlation (HSQC) and heteronuclear multiple bond correlation (HMBC) spectra analysis. This method is considerably more efficient than spectra substraction since results in a clear color alteration and partially obsolescence of a common signals present in two spectra even if those are present in a distinct different concentration (397). The big size of data limits the application of this method. Three different clustering methods, i.e. tree clustering analysis (TCA), K-means clustering and multidimensional scaling, were used to cluster together partially purified plant and marine organism extracts which contain the same bioactive compound or groups of compounds. These clustering methods were chosen to overcome limitations of PCA to handle the data with a large number of clusters or subsets within the data (398). Only a few of the secondary metabolites from *Myxococcus xanthus* have been investigated, in particular some antibiotics such as myxovirescin, saframycin, and althiomyacin. However, only one metabolite unique to *M. xanthus* was known, that is DKxanthanes. Intraspécific diversity in the metabolite profiles of 98 *Myxococcus xanthus* strains originated from 78 locations worldwide was rapidly explored by means of fast chromatographic separation (UPLC)-coupled ESI-TOF-MS and PCA. As a result, 37 candidates for novel compounds were identified but their bioactivities were not reported (399).

5.2. Metabolomics for quality control of phytomedicines

At present, the most popular application of metabolomics in NP research is for the quality control of phytomedicines. Different metabolite profiles may occur due to variations between species or variety, adulteration, environmental changes during
Chapter 4

growth and harvesting, post harvesting treatment, extraction and method of preparation. These factors may significantly alter the efficacy of phytomedicines prepared with these herbs (338). The application of $^1$H NMR combined with multivariate data analysis to detect variations between different herbal preparations has been reported. The most common methods that have been applied for these ends are unsupervised principal component analysis (PCA) and supervised partial least square analysis/partial least square analysis with discriminant analysis (PLS/PLS-DA). These methods were applied to differentiate various chamomile (Matricaria recutita L.) preparations made with plants grown in different locations, percentage of the desired plant part, and extraction method (400). Discrimination between different Cannabis sativa cultivars based on the content of Δ$^9$-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) was achieved (401), as well as discrimination between 11 Ilex species including 2 varieties (402). Similarly, discrimination between Ephedra species (403), and commercial feverfew (Tanacetum parthenium) preparations from different suppliers (2) was obtained. The discrimination of commercial preparations of St. John’s Wort (Hypericum perforatum) from different batches of the same supplier, including variation of flavonoid content which has been previously related to the antidepressant activity was also reported (404). An example of application of GC and GC-MS combined with multivariate data analysis to correlate artemisinin concentration with the growth stage of Artemisia annua L. and to distinguish between transgenic and wild type has been reported (405).

Metabolomics can also be used to detect adulterations of herbal preparations with similar species but with low levels of the desired active compound(s). The $^1$H NMR and PCA was used to verify that the anti-malaria capsules produced by one specific company did not contain Artemisia annua as labeled but Artemisia afra, which has never been reported to contain the active compound artemisinin or any of its derivatives (406). Instead of $^1$H NMR, the use of HPLC fingerprints followed by application of PCA and PLS-DA was applied to examine the authenticity of the traditional Chinese medicines Pericarpium Citri Reticulatae and Pericarpium Citri Reticulatae Viride which contain Citrus reticulate ‘Chachi’, Citrus reticulata ‘Dahongpao’ and Citrus erythrosa Tanaka as well that of commercial preparations
containing a mixture of many tangerine peels which had been made with new tangerine mutations of uncertain quality (407).

5.3. Metabolomics to link chemical profile and bioactivity pattern of phytomedicines

As previously described, a reductionist approach focusing on a single active compound is necessary in some cases, but in case of St. John’s Wort extract, where no single compound or even group of compounds have been found to be responsible for its activity, the possibility of synergism and pro-drugs is evident, and a holistic in-vivo approach would be more valuable to guarantee its therapeutic efficacy (341, 343). Animal experiments and clinical trials are two classical ways to conduct in-vivo experiments, but the time required and costs involved make this option practically non viable. Furthermore, if these tests are performed with extracts of uncertain composition, results will invariably be unreliable or inconsistent. Recently new approaches are evolving which might help to get a better view of the mode of action of herbal or natural products and lead to the possibility of obtaining proof and guarantee of their pharmacological activity over different batches. These approaches are based on considering the NP holistically, i.e. on the bulk of chemical constituents rather than focusing on certain individual components or groups of compounds. On the other hand, the changes caused by a sample on the transcriptome, proteome and/or metabolome patterns can be compared with those observed after treatment with known drugs rather than looking only at certain specific changes. Genomics, proteomics, and metabolomics platforms will be crucial since they allow the identification of detectable protein/genes or compounds which might relate to the biological activity of complex extract (343). This may shift the paradigm in the development and application of complex plant/phytocompound mixtures in modern medicine (408). Moreover, by measuring the effect of a complex extract administered to a living organism, either in-vitro or in-vivo, it is possible to identify the compound or combination of compounds correlated with activity. Besides, new or unsuspected mode(s) of action and targets might also be revealed in this approach (341).

Several papers discussed a metabonomics approach to study various aspects of natural products extracts such as bioavailability, toxicity, and proof of efficacy.
Metabonomics is defined as ‘the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification’ (409). This term is in general equivalent to the NMR spectroscopic analysis of biofluids to identify changes in the concentrations and patterns of endogenous metabolites induced by exogenic compounds (379) but mostly used in medicinal or toxicological studies although sometimes the term metabolomics is also used.

A quick review of the literature reflects the enormous amount of studies that are carried out nowadays using this technology, some representative examples of which are summarized below.

5.3.1. Identification of active compounds and quantitative prediction of bioactivity

Chemometric and $^{1}$H NMR analyses were used to discriminate *Artemisia annua* L samples obtained from different sources. Principal component analysis assignment showed that artemisinin is the main discriminant factor for clustering. Partial least square analysis was applied to predict the quantitative anti-plasmodial activity ($IC_{50}$) and toxicity ($ToxEd_{50}$) value of different *A. annua* extracts. The predictive values were in close agreement with the actual experimental values (3). The same approach was used to demonstrate the correlation between the spectral pattern and opioid receptor binding properties of St. John’s Wort (*Hypericum perforatum*) extracts prepared with different solvents (4). Gas chromatography-MS-based metabolic profiling coupled with anti-inflammatory activity data of ginger (*Zingiber officinale*) from different sources and of some other *Zingiber* species showed that two other closely related *Zingiber* species had similar anti-inflammatory activity to *Z. officinale*, but there was lack of correlation between the content of gingerol, a compound specific to *Z. officinale*, and the observed total anti-inflammatory activity. Therefore, it was concluded that other compounds, unidentified to date which contributed to this activity had to be detected and quantified in order to guarantee the bioactivity of a particular *Zingiber* sample (410). The application of $^{1}$H NMR and PCA analysis allowed the differentiation of six samples of *Galphimia glauca*, a Mexican herbal used to treat central nervous disorders, collected from six different areas. Galphimines and 1,3,4,5-tetra-$O$-galloylquinic acid contents were found to be the main discriminating factors for
PCA separation. Further analysis with PLS-DA confirmed that the level of both compounds was correlated with sedative and anxiolytic effects in mice (5). This technique was also applied successfully to distinguish thrips-resistant and –susceptible F2 hybrids of *Senecio jacobaea* and *Senecio aquaticus*. Pyrrolizidine alkaloids, kaempferol and jacaranone were found to be higher in resistant plants. This is of interest since the last two compounds have positive effects on human health as anti-cancer agents (411).

### 5.3.2. Proof of efficacy and mode of action of herbal medicines

The *in-vitro* cellular effects of *Cannabis* from different cultivars and preparations were analyzed using a proteomic and transcriptomic platform (338). In another case, the *in-vivo* effect of *Ginkgo* on rats was studied by applying a 1H-NMR and supervised MVDA method to measure metabolites in their urine (338). The effect of three traditional Chinese medicines on insulin resistance APOE*3*-Leiden transgenic mice which are highly responsive in their plasmatic lipids to dietary treatments was also studied. The LC-MS measurement combined with MVDA was applied to three TCM preparations to discover which was most effective TCM but had the lowest toxicity (338).

The use of metabolomic profiling to study the mode of action of active natural products recently emerged as well, predominantly in antimicrobial activity analysis. As an example, HPLC/DAD/ESI-MS application followed by PCA confirmed that dihydroocurbitacin F-25-O-acetate was the main component having an antimicrobial activity in *Hemsleya pengxianensis*. The possible antibacterial mode of action on *Staphylococcus aureus* CCTCC AB9105 was predicted by comparing the metabolite profile of *S. aureus* treated by the plant extract and commercial antibacterials with known mode of action (412).

The use of metabonomics to prove the efficacy of herbal medicines was reported in some papers. The evaluation of the anti-ageing effects of the total flavone content of Herba *Epimedii* (TFE), a famous Chinese herbal medicine used to treat some age-related diseases was conducted by 1H NMR analysis and PCA assignment. Ten metabolites were identified as ageing markers in the rat urine profile: creatinine, lactate, alanine, acetate, acetone, succinate, allantoin, methylamine, dimethylamine and
trimethylamine-N-oxide. It showed that after TFE intervention, the 24-month-old rats urine profile was shifted towards that of 18-months-old rats (413). In another case, the study of *Epimedium brevicornum* Maxim, was undertaken. This herbal medicine, one of the most popular in China is used for toning the kidney and strengthening bones, but the kind of constituents responsible for its pharmacological effect, and the mechanism through which it affects the entire body metabolism was unknown. The plasma metabolites of rats from three different treatments (pre-hydrocortisone intervention, post-hydrocortisone intervention, and *Epimedium brevicornum* Maxim. treated) were analyzed using UPLC-MS followed by PCA. The distinct increase of the level of three metabolites was found after hydrocortisone intervention, one of them identified as ethylindole-3-cryl acetate. The result showed that after *Epimedium brevicornum* Maxim treatment, the plasma metabolite profile was restored closer to that of the pre-hydrocortisone intervention. Of the four compounds of this herbal preparation detected in plasma (epimedin C, icariin, icariside II, and 2′″-O-rhamnosoyl icaride), epimedin C and icariin were also found in urine, and it was concluded that those might be the active ones (414).

The efficacy and the mechanism of action of the traditional Chinese medicine preparation known as Xindi soft capsules (consisting of sea buckthorn flavonoids and sea buckthorn berry oil) used to treat blood stasis, was studied by UPLC combined with quadrupole time-of-flight tandem mass spectrometry (UPLC-QTOF-MS) followed by PCA and PLS-DA analysis. Blood stasis includes hematological disorders such as haemorrhage, nasal congestion, thrombosis, and local ischemia (microclots). The comparison of the urinary metabolite pattern obtained for 5 groups of rats (healthy control group, acute blood stasis model group, low dose group of Xindi soft capsule, middle dose group of Xindi soft capsule, high dose group of Xindi soft capsule), showed that the treated groups were located between the acute blood stasis model group and the healthy control group. Confirmation by hemorheological analysis proved that within the treated group, especially in the case of the highest dose group, the urine metabolite pattern tends toward that of the control group. Some potential biomarkers were identified as well, such as cholic acid, phenylalanine and kynurenic acid (415).
5.3.3. Bioavailability and fate of natural compounds assessment

The metabonomics approach was successfully applied to study the bioavailability and fate of natural compounds. A traditional Chinese medicine formulation, Dangguibuxue decoction (ODD) consisting of huangqi (*Radix astragali*)-danggui (*Radix angelicae sinensis*), is widely used as a tonic. Dangguibuxue decoction is a very complex mixture containing hundreds of components. More than 70 compounds have currently been isolated and identified but only a few constituents were reported to be responsible for its activity. Metabolic fingerprinting by LC/DAD-MS was suitable for analysis of the bioavailability of the metabolites of the ODD components *in vivo* by comparing LC/DAD-MS fingerprint of the ODD formula with the metabolite fingerprint of plasma of rabbits treated with ODD. Identification of detected compounds was done by MS and UV spectra comparison with references from literature. Some flavonoids, phtalides, and triterpene saponins, which were known as ODD active compounds were detected, showing that they are well absorbed into the body (416).

5.3.4. Safety and toxicity of herbal medicines assessment

There are also many reports on the application of the metabonomics approach to solve the two other major issues related to the quality control of herbal medicines - safety and toxicity. The mechanism of the toxicity of aristolochic acid was studied by analyzing the urine of rats submitted to intra-peritoneal injection of aristolochic acid and several toxins with known modes of action. The PCA, confirmed by biochemical parameter analysis, allowed researchers to conclude that aristolochic acid induced the damage of renal proximal tubules and medulla, accompanied with a slight hepatic lesion (417). Similarly, the toxicity of Hei-Shun-Pian (the processed lateral root of *Aconitum carmichaelii* Debx., Ranunculaceae) was evaluated using the $^1$H NMR spectral metabolic profile of urine and plasma samples of rats after 5 days oral treatment with the decoction of Hei-Shun-Pian at different doses. Hei-Shun-Pian is a traditional Chinese medicine with analgesic, anti-pyretic, anti-rheumatoid arthritis and anti-inflammatory effects. The C-19 diterpenoid alkaloid aconitine and a series of its derivatives are suggested to be the active principles, but some of those are also very toxic and have narrow therapeutic windows (LD50/ED50). Studying the PCA and PLS analysis of $^1$H NMR data, it was found that the primary differences between the plasma
of treated and the control groups were the increase in the concentration of lipids and the
decrease in the concentration of phosphatidylcholine (PtCho) and O- and N-acetyl
glycoproteins, while taurine, acetate, creatinine, 2-oxoglutarate, dimethylamine and
hippurate levels in urine contributed to the distinction between high and medium dose
groups and control group (418).

Conclusions and perspectives

In response to the renewed interest in NP, several strategies have been
designed to improve NP lead finding. Strategies aimed at improving the compatibility of
natural products with high throughput screening requirements by improving the NP libraries shorten the discovery route, using advanced analytical methods and combining
them with online bioassays, and selecting new approaches which can rapidly provide
evidence of efficacy.

The reductionist approach is still widely used in NP drug discovery studies. However, metabolomics coupled with MVDA can be applied in those cases to speed up
the limiting steps in dereplication and identification of active compounds. This must be
supported by the availability of a high quality open access NP library based on NMR or
MS data. Metabolomics is undoubtedly an important tool for the quality control of
herbal preparations. It captures the differences in the composition due to different
cultivars, growth areas, methods of preparation, and adulterations, all of which might
significantly affect the content of active principles in the preparation.

To explain the chemodiversity offered by Nature in a more intelligent and
innovative way than random studies, HTS can be employed. For this systems biology
based approach, metabolomics is viewed as a crucial tool. Systems biology may allow
the connection between the chemical profile of herbal preparations and the response
given by a living system, either in-vitro or in-vivo. Such a holistic approach to obtain
proof of efficacy has emerged as the new paradigm to detect novel NP in drug
discovery. Significant and obvious advantages are that synergistic interaction can be
detected, as well as prodrugs. At the same time metabolomics will provide information
on the mode of action and include toxic side effects. The capability to quickly analyze a
broad range of metabolites makes metabolomics important in the growing field of
personalized medicine. It allows the metabolic profile of individual patients to be linked
to their response to specific drug therapy as a base to develop a concept on markers of
the efficacy, toxicity, and clearance of drugs, permitting a better prescription for an
individual patient based on their genetic makeup and phenotype status.

It is evident that metabolomics has shown to be a potent facilitator in the
recovery of NP as excellent sources for novel leads, and even further, as a means to
discover novel targets, as the strength of the “omics” based approaches lies greatly in
the fact that results can be stored for long term data mining.
Chapter 4